Twist Bioscience Corporation (NASDAQ:TWST) Receives $49.40 Average Price Target from Brokerages

Key Points

• The average recommendation for Twist Bioscience Corporation (NASDAQ:TWST) is a "Moderate Buy," with nine out of eleven analysts rating it as a buy.
• Twist Bioscience reported a quarterly revenue of $96.06 million, slightly exceeding analyst estimates, while the earnings per share (EPS) was reported at ($0.47).
• Institutional investors have recently increased their stakes in Twist Bioscience, with notable increases from ARK Investment Management and Vanguard Group.

Shares of Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eleven brokerages that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $49.40.

A number of research analysts recently weighed in on the stock. Evercore ISI set a $46.00 price objective on shares of Twist Bioscience in a research note on Monday, August 4th. Cowen reiterated a "buy" rating on shares of Twist Bioscience in a research note on Monday, August 4th.

Insiders Place Their Bets

In other news, CEO Emily M. Leproust sold 2,265 shares of the business's stock in a transaction on Monday, September 8th. The shares were sold at an average price of $25.76, for a total transaction of $58,346.40. Following the completion of the transaction, the chief executive officer directly owned 634,740 shares in the company, valued at $16,350,902.40. The trade was a 0.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Adam Laponis sold 2,449 shares of the business's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $38.15, for a total transaction of $93,429.35. Following the transaction, the chief financial officer owned 103,569 shares of the company's stock, valued at $3,951,157.35. This trade represents a 2.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 6,805 shares of company stock valued at $211,868 over the last 90 days. Company insiders own 3.01% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in TWST. Versant Capital Management Inc grew its position in shares of Twist Bioscience by 547.2% during the 1st quarter. Versant Capital Management Inc now owns 686 shares of the company's stock valued at $27,000 after purchasing an additional 580 shares in the last quarter. GAMMA Investing LLC grew its position in Twist Bioscience by 68.1% in the first quarter. GAMMA Investing LLC now owns 748 shares of the company's stock worth $29,000 after acquiring an additional 303 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in Twist Bioscience in the fourth quarter worth $58,000. Mirae Asset Global Investments Co. Ltd. grew its position in Twist Bioscience by 15.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company's stock worth $85,000 after acquiring an additional 302 shares in the last quarter. Finally, Geneos Wealth Management Inc. purchased a new position in Twist Bioscience in the second quarter worth $97,000.

Twist Bioscience Stock Performance

Shares of NASDAQ:TWST traded up $0.07 during mid-day trading on Monday, reaching $28.02. The company had a trading volume of 517,803 shares, compared to its average volume of 1,223,432. Twist Bioscience has a one year low of $24.07 and a one year high of $55.33. The firm has a market cap of $1.69 billion, a price-to-earnings ratio of -19.27 and a beta of 2.31. The company has a current ratio of 3.90, a quick ratio of 3.60 and a debt-to-equity ratio of 0.03. The company's 50-day moving average price is $29.67 and its 200-day moving average price is $33.93.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.07. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. The business had revenue of $96.06 million during the quarter, compared to analyst estimates of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, equities research analysts anticipate that Twist Bioscience will post -2.12 EPS for the current fiscal year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.